 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
23 News |  |
- | insulin oral (NN1954) / Novo Nordisk
Journal: The upregulated intestinal folate transporters direct the uptake of ligand-modified nanoparticles for enhanced oral insulin delivery. (Pubmed Central) - May 10, 2022
Overall, we emphasize that the upregulated intestinal transporters could direct the uptake of ligand-modified nanoparticles by mediating the endocytosis and intracellular trafficking of ligand-modified nanoparticles via the transporter-mediated pathway. This study may also theoretically provide insightful guidelines for the rational design of transporter-targeted nanoparticles to achieve efficient drug delivery in diverse diseases.
- || insulin oral (NN1954) / Novo Nordisk
Clinical, Review, Journal, HEOR: Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. (Pubmed Central) - Apr 1, 2022
In conclusion, better adherence and persistence in people with T2D is associated with lower rates of microvascular and/or macrovascular outcomes and inpatient hospitalization, and lower or budget-neutral total healthcare expenditure. Education and treatment strategies to address suboptimal adherence and persistence are needed to improve clinical and economic outcomes.
- | insulin oral (NN1954) / Novo Nordisk
Our recent article on #oral #insulin delivery. Feedback is appreciated @Bioconlimited @kiranshaw @novonordisk @NanomedicineICT @ICTMumbai1933 https://t.co/46fWvRqsBB (Twitter) - Mar 31, 2022
- || verapamil / Generic mfg.
Review, Journal: Current and future therapies for type 1 diabetes. (Pubmed Central) - Feb 23, 2022
Whilst autoimmune-focused prevention approaches are central in type 1 diabetes and will be a requirement in the advent of stem cell-based replacement therapies, managing the primarily cardiometabolic complications of established type 1 diabetes is equally essential. In this review, we outline selected recent and suggested future attempts to address the evolving profile of the person with type 1 diabetes.
- | insulin oral (NN1954) / Novo Nordisk
Journal: Intraintestinal and Parenteral Administration of an Insulin Analogue Leads to Comparable Activation of Signaling Downstream of the Insulin Receptor in the Small Intestine. (Pubmed Central) - Jun 28, 2021
Treatment with I106 resulted in activation of Akt in the intestine, with no significant difference between the effects of ii or iv administration. The results from this rat model of orally administered insulin indicate that the unabsorbed insulin in the intestinal lumen after oral administration will not result in an enhanced acute effect in the intestine.
- || metformin / Generic mfg., Lantus (insulin glargine) / Sanofi
Clinical, P2 data, Journal: Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. (Pubmed Central) - May 23, 2020
P2
Further development of this particular oral insulin project was discontinued because I338 doses were high and, therefore, production of the required quantities of I338 for wide public use was deemed not commercially viable. Improvement of technologies involved in the product's development is the focus of ongoing research.
- ||| insulin oral (NN1954) / Novo Nordisk
Trial completion: A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects (clinicaltrials.gov) - Nov 7, 2012
P1, N=83, Completed, Sponsor: Novo Nordisk
Improvement of technologies involved in the product's development is the focus of ongoing research. Recruiting --> Completed
- ||| insulin oral (NN1954) / Novo Nordisk
New P1 trial: A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects (clinicaltrials.gov) - May 10, 2012
P1, N=83, Completed, Sponsor: Novo Nordisk